Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Tue, 04/22/2014 - 8:22am

Elite Pharmaceuticals announced today the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent expands the intellectual property for the company's opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe.

"We are pleased with this additional patent coverage," stated Nasrat Hakim, President and CEO of Elite. "Elite's abuse deterrent program has made significant progress. In December, a successful pilot bioequivalence study for ELI-201 was completed and in January a successful pivotal bioequivalence study for ELI-200 was completed.
These products are the first of our many abuse deterrent opioid products under development."

About Elite's Abuse Deterrent Technology

Elite's abuse deterrent products utilize the company's proprietary pharmacological abuse deterrent technology. Elite's abuse deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.